Pronounced state-level variation in Medicaid prescription of cannabinoidsMedicalResearch.com Interview with:Edward Liu, BASecond year medical studentDepartment of Medical EducationGeisinger Commonwealth School of MedicineScranton, PAMedicalResearch.com: What is the background for this study? Response: The use pattern of two FDA approved cannabinoids, dronabinol (Marinol) and cannabidiol (Epidiolex) has not been previously studied. Response: Dronabinol and cannabidiol demonstrated pronounced state-level disparities in prescriptions.4 Dronabinol average prescriptions per state decreased by a quarter (-25.3%) from 2016 to 2020, while that of cannabidiol showed a pronounced increase of 16,272.99 % from 2018 to 2020. Response: The prescriptions of dronabinol decreased while that of cannabidiol increased from 2016-2020, with both cannabinoids showing pronounced state level variations in prescribing to Medicaid patients. Pronounced state-level disparities in prescription of cannabinoids to Medicaid patients.

Source: Forbes July 07, 2023 23:07 UTC